Pieris Pharmaceuticals, Inc. (PIRS)

$17.01

-0.3

(-1.73%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $16.54
    $17.93
    $17.01
    downward going graph

    2.75%

    Downside

    Day's Volatility :7.74%

    Upside

    5.13%

    downward going graph
  • $6.20
    $41.78
    $17.01
    downward going graph

    63.55%

    Downside

    52 Weeks Volatility :85.16%

    Upside

    59.29%

    downward going graph

Returns

PeriodPieris Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
47.7%
6.5%
0.0%
6 Months
31.94%
7.1%
0.0%
1 Year
0.64%
9.8%
0.0%
3 Years
-93.56%
14.2%
-20.2%

Highlights

Market Capitalization
20.6M
Book Value
$17.76
Earnings Per Share (EPS)
-11.4
PEG Ratio
0.0
Wall Street Target Price
7.0
Profit Margin
-39.71%
Operating Margin TTM
-10005.66%
Return On Assets TTM
-6.3%
Return On Equity TTM
-86.86%
Revenue TTM
40.9M
Revenue Per Share TTM
34.04
Quarterly Revenue Growth YOY
-97.3%
Gross Profit TTM
-27.1M
EBITDA
-3.9M
Diluted Eps TTM
-11.4
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Pieris Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Downside of 58.85%

Current $17.01
Target $7.00

Company Financials

FY18Y/Y Change
Revenue
29.1M
↑ 15.14%
Net Income
-26.8M
↑ 51.61%
Net Profit Margin
-91.93%
↓ 22.11%
FY19Y/Y Change
Revenue
46.3M
↑ 59.03%
Net Income
-23.8M
↓ 11.21%
Net Profit Margin
-51.33%
↑ 40.6%
FY20Y/Y Change
Revenue
29.3M
↓ 36.64%
Net Income
-37.2M
↑ 56.72%
Net Profit Margin
-126.97%
↓ 75.64%
FY21Y/Y Change
Revenue
31.4M
↑ 7.14%
Net Income
-43.4M
↑ 16.48%
Net Profit Margin
-138.03%
↓ 11.06%
FY22Y/Y Change
Revenue
25.9M
↓ 17.56%
Net Income
-31.3M
↓ 27.93%
Net Profit Margin
-120.66%
↑ 17.37%
FY23Y/Y Change
Revenue
42.8M
↑ 65.28%
Net Income
-24.5M
↓ 21.47%
Net Profit Margin
-57.33%
↑ 63.33%
Q4 FY22Q/Q Change
Revenue
5.8M
↑ 8.86%
Net Income
-8.1M
↓ 5.33%
Net Profit Margin
-138.15%
↑ 20.71%
Q1 FY23Q/Q Change
Revenue
1.9M
↓ 66.88%
Net Income
-12.3M
↑ 52.45%
Net Profit Margin
-635.95%
↓ 497.8%
Q2 FY23Q/Q Change
Revenue
20.1M
↑ 935.9%
Net Income
4.0M
↓ 132.29%
Net Profit Margin
19.83%
↑ 655.78%
Q3 FY23Q/Q Change
Revenue
19.5M
↓ 2.67%
Net Income
-10.8M
↓ 370.42%
Net Profit Margin
-55.08%
↓ 74.91%
Q4 FY23Q/Q Change
Revenue
1.3M
↓ 93.35%
Net Income
-4.6M
↓ 57.37%
Net Profit Margin
-352.89%
↓ 297.81%
Q1 FY24Q/Q Change
Revenue
53.0K
↓ 95.92%
Net Income
-4.9M
↑ 6.72%
Net Profit Margin
-9.2K%
↓ 8877.3%
FY18Y/Y Change
Total Assets
141.3M
↑ 36.07%
Total Liabilities
101.4M
↑ 9.8%
FY19Y/Y Change
Total Assets
141.1M
↓ 0.17%
Total Liabilities
89.7M
↓ 11.5%
FY20Y/Y Change
Total Assets
105.0M
↓ 25.58%
Total Liabilities
74.0M
↓ 17.56%
FY21Y/Y Change
Total Assets
153.6M
↑ 46.23%
Total Liabilities
102.8M
↑ 38.96%
FY22Y/Y Change
Total Assets
95.5M
↓ 37.82%
Total Liabilities
67.6M
↓ 34.28%
FY23Y/Y Change
Total Assets
38.7M
↓ 59.49%
Total Liabilities
11.9M
↓ 82.35%
Q4 FY22Q/Q Change
Total Assets
95.5M
↓ 3.7%
Total Liabilities
67.6M
↑ 6.57%
Q1 FY23Q/Q Change
Total Assets
82.3M
↓ 13.86%
Total Liabilities
66.8M
↓ 1.13%
Q2 FY23Q/Q Change
Total Assets
87.5M
↑ 6.43%
Total Liabilities
47.0M
↓ 29.57%
Q3 FY23Q/Q Change
Total Assets
59.4M
↓ 32.18%
Total Liabilities
28.9M
↓ 38.64%
Q4 FY23Q/Q Change
Total Assets
38.7M
↓ 34.86%
Total Liabilities
11.9M
↓ 58.7%
Q1 FY24Q/Q Change
Total Assets
29.5M
↓ 23.74%
Total Liabilities
7.5M
↓ 36.81%
FY18Y/Y Change
Operating Cash Flow
-1.1M
↓ 102.14%
Investing Cash Flow
-8.9M
↓ 80.65%
Financing Cash Flow
48.5M
↑ 1086.09%
FY19Y/Y Change
Operating Cash Flow
-52.5M
↑ 4821.86%
Investing Cash Flow
9.8M
↓ 210.85%
Financing Cash Flow
32.2M
↓ 33.69%
FY20Y/Y Change
Operating Cash Flow
-45.9M
↓ 12.52%
Investing Cash Flow
39.2M
↑ 298.58%
Financing Cash Flow
10.1M
↓ 68.55%
FY21Y/Y Change
Operating Cash Flow
-7.7M
↓ 83.31%
Investing Cash Flow
-949.0K
↓ 102.42%
Financing Cash Flow
59.1M
↑ 484.55%
Q4 FY22Q/Q Change
Operating Cash Flow
-12.9M
↑ 47.33%
Investing Cash Flow
-1.4M
↓ 124.97%
Financing Cash Flow
93.0K
↓ 67.02%
Q1 FY23Q/Q Change
Operating Cash Flow
-11.0M
↓ 14.98%
Investing Cash Flow
11.9M
↓ 971.38%
Financing Cash Flow
19.8M
↑ 21169.89%
Q2 FY23Q/Q Change
Operating Cash Flow
-13.4M
↑ 22.14%
Investing Cash Flow
-1.4M
↓ 111.48%
Financing Cash Flow
19.8M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Pieris Pharmaceuticals, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
98.51%
31.94%
0.64%
-93.56%
-95.44%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
NA
NA
0.0
0.0
-0.87
-0.06
NA
17.76
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
Sell
$20.6M
-95.44%
NA
-39.71%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Pieris Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 20.05M → 53.0K (in $), with an average decrease of 64.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -4.58M → -4.89M (in $), with an average decrease of 6.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 61.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 280.1%

Institutional Holdings

  • Renaissance Technologies Corp

    1.01%

  • BlackRock Inc

    0.98%

  • Acadian Asset Management LLC

    0.91%

  • Vanguard Group Inc

    0.86%

  • Geode Capital Management, LLC

    0.72%

  • Northern Trust Corp

    0.23%

Company Information

pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche

Organization
Pieris Pharmaceuticals, Inc.
Employees
46
CEO
Mr. Stephen S. Yoder J.D.
Industry
Health Technology

Discover More

FAQs